Literature DB >> 17976085

Japanese Society of Dialysis Therapy treatment guidelines for secondary hyperparathyroidism.

Junichiro James Kazama1.   

Abstract

Impairment of renal function causes various abnormalities of bone mineral metabolism including secondary hyperparathyroidism. The Japanese Society of Dialysis Therapy proposed the guidelines for the treatment of secondary hyperparathyroidism in chronic dialysis patients (JSDT guidelines) in 2006. From the perspective of better survival rate, the control goal value was determined to be 3.5-6 mg/dl for phosphorus, 8.4-10.0 mg/dl for calcium, and 60-180 pg/ml for intact PTH levels. When the 3 items cannot be controlled by treatment with an active vitamin D preparation, treatment is considered to be a failure, and intervention treatment of the parathyroid gland is recommended. The adequacy of the JSDT guideline must be evaluated by its clinical application.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17976085     DOI: 10.1111/j.1744-9987.2007.00516.x

Source DB:  PubMed          Journal:  Ther Apher Dial        ISSN: 1744-9979            Impact factor:   1.762


  9 in total

1.  Serum alkaline phosphatase and infection-related mortality in hemodialysis patients: ten-year outcomes of the Q-cohort study.

Authors:  Hiromasa Kitamura; Ryusuke Yotsueda; Hiroto Hiyamuta; Masatomo Taniguchi; Shigeru Tanaka; Shunsuke Yamada; Kazuhiko Tsuruya; Toshiaki Nakano; Takanari Kitazono
Journal:  Clin Exp Nephrol       Date:  2022-08-04       Impact factor: 2.617

2.  Long-term cinacalcet HCl treatment improved bone metabolism in Japanese hemodialysis patients with secondary hyperparathyroidism.

Authors:  Takashi Shigematsu; Tadao Akizawa; Eiji Uchida; Yusuke Tsukamoto; Manabu Iwasaki; Shouzo Koshikawa
Journal:  Am J Nephrol       Date:  2008-09-17       Impact factor: 3.754

3.  Cardiac valvular surgery in dialysis patients: comparison of surgical outcome for mechanical versus bioprosthetic valves.

Authors:  Kentaro Umezu; Satoshi Saito; Kenji Yamazaki; Akihiko Kawai; Hiromi Kurosawa
Journal:  Gen Thorac Cardiovasc Surg       Date:  2009-04-15

4.  Clinical significance of parathyroid intervention on CKD-MBD management.

Authors:  Hiroaki Ogata; Masahide Mizobuchi; Fumihiko Koiwa; Eriko Kinugasa; Tadao Akizawa
Journal:  NDT Plus       Date:  2008-08

5.  High fibroblast growth factor 23 levels are associated with decreased ferritin levels and increased intravenous iron doses in hemodialysis patients.

Authors:  Hirokazu Honda; Tetsuo Michihata; Kanji Shishido; Keiko Takahashi; Go Takahashi; Nozomu Hosaka; Misa Ikeda; Daisuke Sanada; Takanori Shibata
Journal:  PLoS One       Date:  2017-05-05       Impact factor: 3.240

6.  Impact of nutritional index on the association between phosphorus concentrations and mortality in haemodialysis patients: a cohort study from dialysis outcomes and practice pattern study in Japan.

Authors:  Shingo Fukuma; Tatsuyoshi Ikenoue; Tadao Akizawa; Shunichi Fukuhara
Journal:  BMJ Open       Date:  2017-08-07       Impact factor: 2.692

7.  Use of phosphate-binders and risk of infection-related and all-cause mortality in patients undergoing hemodialysis: The Q-Cohort Study.

Authors:  Shunsuke Yamada; Masanori Tokumoto; Masatomo Taniguchi; Hisako Yoshida; Hokuto Arase; Narihito Tatsumoto; Hideki Hirakata; Takanari Kitazono; Kazuhiko Tsuruya
Journal:  Sci Rep       Date:  2018-07-30       Impact factor: 4.379

8.  Intravenous calcitriol therapy in an early stage prevents parathyroid gland growth.

Authors:  Masatomo Taniguchi; Masanori Tokumoto; Kazuhiko Tsuruya; Hideki Hirakata; Mitsuo Iida
Journal:  Nephrol Dial Transplant       Date:  2008-05-30       Impact factor: 5.992

9.  Prescribing Hemodialysis or Hemodiafiltration: When One Size Does Not Fit All the Proposal of a Personalized Approach Based on Comorbidity and Nutritional Status.

Authors:  Giorgina Barbara Piccoli; Louise Nielsen; Lurilyn Gendrot; Antioco Fois; Emanuela Cataldo; Gianfranca Cabiddu
Journal:  J Clin Med       Date:  2018-10-08       Impact factor: 4.241

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.